Ulta Beauty enters the back half of September with a contradictory setup: an analyst upgrade from one of its most vocal bears arrived on the same morning that short interest hit its highest level in three weeks.
The short positioning story is the week's clearest tension. Short interest climbed 16% over the past five days, reaching 5% of the free float — the fastest weekly build since early August. That move followed a distinct step-change visible in the history: shorts had been running near 1.94 million shares through late August, then jumped sharply on September 9 to 1.97 million and kept climbing, reaching 2.26 million by Tuesday. Despite the surge, the borrow market remains far from strained. Availability is a very loose 1,767% — meaning roughly 17 shares remain available to borrow for every one already lent out, well above even the year's tightest reading of 980%. Cost to borrow rose 52% on the week to 0.58%, but at that level it still qualifies as cheap. The options market tells a similar non-panicked story: the put/call ratio of 0.93 is essentially flat against its 20-day average of 0.93, with a z-score near zero. Positioning looks notably busier on the short side this week, but the lending infrastructure shows none of the tightness that would signal real squeeze risk.
The Street pivot is the more immediate headline. Wells Fargo's Ike Boruchow upgraded to Equal-Weight from Underweight on September 15, lifting his target from $450 to $525 — the most newsworthy single action this week, given the firm's prior bearish stance. That move comes while the stock trades at $544, meaning Boruchow still sees the current price as roughly fair rather than cheap. The broader analyst picture is mixed. Following the August 27 earnings release, Goldman Sachs raised its target to $667, DA Davidson lifted to $625, and Deutsche Bank moved to $695 — all maintaining Buy-equivalent ratings. In the same session, BofA trimmed to $650 from $685 and UBS cut to $710 from $735 while keeping buys intact. BMO Capital initiated at Market Perform with a $580 target on September 9. The consensus sits at Hold, with a mean target of $630.64 — implying roughly 16% upside from here on paper. The PE multiple of 17.6x and EV/EBITDA of 12.1x have drifted higher over 30 days alongside the stock's 6.6% monthly gain, though both remain modest for specialty retail.
The bull and bear cases reflect the same August earnings print seen through different lenses. Bulls point to comparable sales growth of 5.8% — ahead of expectations and a clear acceleration — and e-commerce running at mid-teens growth in the second half of 2025. FY26 revenue growth of 6-7% is now the base case, with EBIT margins projected above 12.5%. Bears focus on gross margin slipping to 38.1% and adjusted EPS of $8.01 missing the consensus, alongside the ending Target partnership, rising operating costs, and persistent competitive pressure from mass-market beauty brands. The ORTEX short score of 41 has edged higher from 38.3 two weeks ago — ranking in the 38th percentile for short pressure — consistent with a stock that attracts incremental short interest but sits nowhere near extreme territory.
Institutional ownership gives little away. T. Rowe Price is the standout active manager move in recent data, having added 446,163 shares to reach a 5.6% stake reported as of September 1. Sanders Capital built a comparably sized position over the same period, adding 552,830 shares. BlackRock holds 9.4% and Vanguard Capital 7.2%, both essentially steady. On the insider side, the only open-market transaction in the past 90 days was a director sell of 600 shares at $537 on September 11 — modest in size and carried no 10b5-1 plan flag, though the value ($322K) is too small to read as a strong conviction signal. Net insider activity over 90 days is marginally negative at roughly -$505K.
Earnings are next due December 3. The August print delivered a one-day drop of 4.7%, followed by a five-day recovery of 2.6% — a pattern that would be worth watching if short interest continues building into year-end. For now, the key variable is whether the Wells Fargo upgrade and the institutional buying from T. Rowe and Sanders form a floor under the stock, or whether the renewed short build reflects genuine concern that the August beat-on-revenue, miss-on-margin setup repeats at the December print, with peers like FIVE (down 7% this week) and AEO (down 14%) already flagging a softer consumer backdrop.
See the live data behind this article on ORTEX.
Open ULTA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
